SCI & TECH● LOWSep 8 · Sep 8, 2026, 12:55 PM
Intellia rises on FDA priority review for one-time hereditary angioedema therapy
Seeking Alpha Tech · north america
Intellia's stock has risen after its one-time hereditary angioedema therapy received priority review from the FDA. This indicates a fast-tracked regulatory assessment for a potential new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH31m agoMeta Launches New ‘Open’ AI Model To Rival Chinese CompetitionChannels TVSCI & TECH31m agoMeta unveils new ‘open’ AI model to rival Chinese competitionVanguard NigeriaSCI & TECH54m agoAnavex Life Sciences gains IND clearance for blarcamesine in Fragile X syndromeSeeking Alpha TechSCI & TECH58m agoAstra | The latest leapThe Hindu